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Differential expression of 
microRNAs and other small RNAs in 
muscle tissue of patients with ALS 
and healthy age-matched controls
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Stanislava Ristic Kovacic2, Tomaž Curk  4 & Boris Rogelj  1,5,6
Amyotrophic lateral sclerosis is a late-onset disorder primarily affecting motor neurons and leading to 
progressive and lethal skeletal muscle atrophy. Small RNAs, including microRNAs (miRNAs), can serve 
as important regulators of gene expression and can act both globally and in a tissue-/cell-type-specific 
manner. In muscle, miRNAs called myomiRs govern important processes and are deregulated in various 
disorders. Several myomiRs have shown promise for therapeutic use in cellular and animal models of 
ALS; however, the exact miRNA species differentially expressed in muscle tissue of ALS patients remain 
unknown. Following small RNA-Seq, we compared the expression of small RNAs in muscle tissue of ALS 
patients and healthy age-matched controls. The identified snoRNAs, mtRNAs and other small RNAs 
provide possible molecular links between insulin signaling and ALS. Furthermore, the identified miRNAs 
are predicted to target proteins that are involved in both normal processes and various muscle disorders 
and indicate muscle tissue is undergoing active reinnervation/compensatory attempts thus providing 
targets for further research and therapy development in ALS.
Amyotrophic lateral sclerosis (ALS) is a late-onset disorder primarily affecting upper and lower motor neurons 
leading to progressive and severe skeletal muscle atrophy. Whether the denervation is initiated primarily in the 
CNS or by the muscle itself remains under debate1. What is becoming increasingly clear, however, is that a com-
plex molecular interplay contributes to this disorder, of which many components are closely involved in RNA 
metabolism.
One of the main pathogenic features of ALS are cytoplasmic aggregates of an otherwise predominantly nuclear 
DNA- and RNA-binding protein TDP-43 (TAR DNA-binding protein) in affected neurons, however, mutations of 
this protein in patients are too rare to explain this phenomenon2–4. TDP-43 is an RNA processing protein and is 
known to be intricately involved in RNA metabolism5–7. In addition to TDP-43, mutations and mislocalizations of 
other RNA-binding proteins, such as FUS and other hnRNPs (heterogeneous ribonucleoprotein) have also been 
shown to be associated with ALS8–13. The intronic (G4C2) hexanucleotide repeat expansion within the C9ORF72 
gene has been shown to be the main genetic feature of ALS14–16. As well as giving rise to exotic DNA features such 
as G-quadruplexes and i-motifs17,18, the expanded repeats undergo both aberrant and unconventional processing 
(reviewed in Vatovec et al.19), which further supports disease-associated changes in RNA metabolism as a core 
mechanism in ALS pathogenesis.
MicroRNAs (miRNAs) are around 22 nucleotide long non-coding RNA molecules that serve as regulators 
of transcriptional and post-transcriptional gene expression20,21. They regulate their target messenger RNAs 
(mRNAs) through either their binding and inactivation and/or degradation22. A single miRNA may often bind 
up to several hundred mRNAs, while several different miRNAs can bind the same mRNA23,24. Muscle miRNAs or 
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myomiRs are a large group of miRNAs enriched in skeletal and/or cardiac muscle. Although many myomiRs are 
exclusive for muscle tissue, some can also be found in other tissues. MyomiRs are normally involved in processes 
such as myogenesis and muscle homeostasis but can become differentially expressed both in general atrophy 
(due to immobility or caloric restriction) and muscle disorders (reviewed in Kovanda et al.25). So far over 200 
myomiRs have been shown to be deregulated in different pathological conditions, such as Duchenne muscular 
dystrophy (DMD), Becker muscular dystrophy, facioscapulohumeral muscular dystrophy, limb-girdle muscular 
dystrophies, Miyoshi myopathy, nemaline myopathy, polymyositis, dermatomyositis, inclusion body myositis, 
etc.26–28. At the same time, several myomiRs have also shown potential as targets for therapeutic intervention in 
various models of muscular atrophy29–33.
In ALS, information on global miRNA expression is lacking, and the expression of only 7 miRNAs, involved 
in the regulation of HDAC4, has recently been examined34 in the muscle tissue of ALS patients. MiR-206 and 
miR-133b have been reported to be increased on disease onset in a SOD-1-G93A ALS mouse model35, with miR-
206 KO mice showing delayed reinnervation, an increase in HDAC4, and faster disease progression compared to 
SOD-1-G93A controls. However, only miR-155, which is increased in the spinal cord of ALS patients, has so far 
been used as a non-muscle therapeutic target in ALS, its inhibition extending the survival SOD-1-G93A mice36, 
despite promising results with myomiR targeting in other muscle disorder models such as Duchenne muscular 
dystrophy and spinal and bulbar muscular atrophy37,38.
Despite the relatively high evolutionary conservation of miRNAs, the molecular differences between humans 
and existing animal and cellular models of ALS39 mean the information on global miRNA expression in ALS 
patients is crucial for any future therapy design.
The aim of our study was to determine the global differential expression of miRNAs and other small RNAs in 
the muscle tissue of ALS patients using small RNA Seq, in order to suggest novel disease mechanisms and identify 
most likely candidates for novel directions in therapy development.
Results
Patients and controls. We obtained muscle biopsies from 12 patients with ALS and 11 control subjects, 
however, due to low RNA integrity number (RIN) one patient sample was excluded from the analysis. The average 
age of patients vs. controls was 62.2 (±11.1) vs. 61.1 (±12.3) years, and females constituted 45.5% (5/11) and 
54.5% (6/11) of patients and controls included in the study, respectively. The mean age of patients at disease onset 
was 58.0 (±10.9) years. 72.7% (8/11) of patients had spinal and 27.3% (3/11) had bulbar disease onset. 54.5% 
(6/11) patients had definite, 27.3% (3/11) had a probable, and 18.2% (2/11) had a possible ALS diagnosis accord-
ing to revised El Escorial criteria40. Genetic analyses were previously performed for 54.5% (6/11) patients, with no 
known ALS related mutations discovered41. 18.2% (2/11) patients had a family history of the disease. Clinically, 
all patients had both lower and upper motor neuron involvement. The ALS FRS score of patients ranged from 18 
to 43 (average 28.3 (±6.9)), however only patients who could walk were included in the study as we assumed that 
the severity of muscle atrophy in immobile patients would not allow for adequate comparison of muscle tissue. 
Therefore, all patients had ALS FRS walking scores above 1, and all but 2 patients could still use stairs to some 
extent. The biopsy was performed on the less affected leg in all cases. Detailed characteristics of patients and 
controls are shown in Table 1.
Next generation sequencing. Based on the quality control (QC) of sample isolation prior to library prepa-
ration, one patient sample (ALS 5) was excluded from further analyses based on its low RIN. 75 base single strand 
small RNA next-generation sequencing of 22 samples was performed on the NextSeq 500 instrument using the 
high output flow cell format. One human brain total RNA sample was analyzed in parallel as a positive control. 
Raw data have been deposited to NCBI’s Gene Expression Omnibus42,43 and are accessible through GEO Series 
accession number GSE100188. Trimming and sequence QC was performed commercially by IMGM Laboratories 
GmbH using CLC Genomics Workbench 8.5.1 (CLC bio). The tags were then annotated using small RNA data-
bases human miRBase 21 and Ensemble Non-coding RNA (GRCh38ncrna). In total between 22.1% and 30.8% 
reads could be annotated in this way, using both databases (Fig. 1, Supplementary Table S1).
Differential expression. Both annotated and unannotated small RNA tags were analyzed for significantly 
differentially expressed small RNAs in two separate CLC Genomics Workbench experiments. The p-value was 
calculated using the Baggerly’s test44 and the p-value was FDR-corrected by using the Benjamini and Hochberg 
method45. Only tags with at least 5 read counts were included in the analysis. Significant results include only those 
differentially expressed small RNAs with an FDR corrected p-value ≤0.05 and fold-change FC ≥2.0. The sum-
mary overview of the changed small RNAs is given by Fig. 1.
Of the unannotated tags, 117 were significantly (FDR corrected p-value ≤0.05) up-regulated (FC ≥2.0), while 
641 were significantly down-regulated (FC ≤2.0, see Supplementary Table S2 and S3, respectively). Many of the 
unannotated tags could be assigned to a specific genomic location or several genomic locations using BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi). The analysis of these sequences is not yet part of established bioinfor-
matic pipelines and is made difficult either because of their mapping to many or poorly characterized genomic 
locations. Although these tags may represent potential novel miRNAs or other small RNAs that could be involved 
in the pathogenesis of ALS, they will be analyzed in depth as part of a separate study.
Data quality assessment was subsequently performed with sample clustering and visualization using DESeq46 
(Figs 1, 2 and 3). MA plots of all annotated and unannotated tags are shown in Fig. 1B. The principal component 
analysis plot (PCA) showed four ALS samples and one control sample did not cluster with their respective groups. 
Based on the PCA (Fig. 2) and sample clustering (Fig. 3), that indicated a high presence of miRNAs (such as miR-
143) associated with fat tissue, the control sample in question (K10) was excluded from the further analysis using 
DESeq. The subsequent check of the control’s weight showed a high BMI, suggesting a higher intramuscular fat 
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content, which supports this result. Results of DESeq comparisons of all ALS patients against controls without 
control K10 (Supplementary Table S4) are summarized in Table 2.
Among the annotated tags, the CLC Genomic Workbench experiment identified a total of 134 tags that dif-
fered significantly between the ALS and control groups. Within the 115 up-regulated annotated tags, 19 groups of 
miRNAs and 24 other ncRNAs were represented (Supplementary Table S5), while within the 19 down-regulated 
annotated tags, 10 groups of miRNAs and 5 ncRNAs were represented (Supplementary Table S6), respectively. 
The DESeq calculation re-identified 6 of these differentially expressed miRNAs and 11 of the differentially 
expressed other small RNAs with FDR statistical significance, as well as identified additional 7 miRNAs and 8 
other small RNAs, respectively (Fig. 1C,D).
The four ALS samples (ALS 4, ALS 7, ALS 8, and ALS 9) that were nested within the control group in the PCA 
analysis all had high leg-use scores (walking and using steps) and only one of the patients had a definite ALS 
diagnosis (Table 1). This particular patient happened to be the youngest of our patients at 45 years of age. These 
factors, combined with our choice of the less affected leg, may explain these results. This is also in line with the 
hypothesis that active muscle regeneration attempts precede the development of noticeable clinical atrophy in 
case of ALS1,34, and thus in our case may mask some disease-associated changes.
Therefore, we also separated the ALS patients into two groups, group 1 (patients ALS 1, ALS 2, ALS 3, ALS 6, 
ALS 10, ALS 11, ALS 12), and group 2 (patients ALS 4, ALS 7, ALS 8, and ALS 9) and compare them to controls 
with the aim of identifying any group-specific molecular markers that could be associated with disease severity.
Comparisons of ALS group 1 with controls excluding K10 (Supplementary Table S7), indeed resulted in the 
identification of 11 additional microRNA groups as well as 50 other small ncRNAs, among them 2 retired novel 
miRNAs, 26 snoRNAs, and 5 mitochondrial RNAs (Table 2 and Fig. 1C,D). However, the results of DESeq com-
parisons of ALS group 2 patients with controls excluding K10 (Supplementary Table S8) did not show any signif-
icantly changed miRNAs and only showed one significantly changed ncRNA, which was snoRNA-116 (Table 2, 
Fig. 1C,D). This may be interesting in that it may represent an early marker of disease and will be further dis-
cussed below (See other differentially expressed small RNAs.).
Target, KEGG, and GO analyses of differentially expressed miRNAs. In silico Tarbase analysis of 
miRNA targets based on the comparison of all patients against all controls showed over 14,000 genes to be tar-
geted, some of which by more than one of the differentially expressed miRNAs. Of these targets, approx. 40 have 
already been implicated in neuronal ALS pathology or other disorders involving muscle wasting, while several 
hundred others are suggested to be involved in muscle contraction, muscle organ development, skeletal muscle 
cell differentiation, muscle morphogenesis etc. (Supplementary Table S9).
KEGG pathways (Fig. 4) and GO genes union analyses were performed on targets of all differentially expressed 
miRNAs identified by both the Baggerly’s test as well as the various DESeq group analyses (Supplementary 
Tables S10 and S11). Of note is that the top hits among the KEGG pathways (Fig. 4) include signaling pathways 
regulating pluripotency of stem cells, ubiquitin-mediated proteolysis, axon guidance, regulation of actin cytoskel-
eton, and TGF-beta signaling pathway which could be expected to be affected in a tissue undergoing both degen-
erative/apoptotic and regenerative processes. Additionally, both fatty acid biosynthesis and metabolism have been 
previously implicated in ALS and may present targets for therapy development47. Although cancer pathways, 
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ALS-01 F probable 63 67 no S 3 L/U no 32 4 4 4 3 0 — 0 3 2 1 3 3 4 4 5
ALS-02 F definite 50 51 nd S 4 L/U yes 34 4 3 3 4 4 — 1 0 3 0 3 4 4 4 5
ALS-03 F definite 65 68 no S 4 L/U no 22 3 1 3 3 0 — 0 0 1 0 1 4 3 4 4
ALS-04 M probable 77 80 nd B 4 L/U no 18 0 0 1 1 1 — 0 0 3 1 4 4 4 3 5
ALS-05 F possible 59 64 nd S 1 L* no 43 4 4 4 4 4 — 4 4 2 1 3 4 4 4 nd
ALS-06 F definite 70 71 nd B 4 L/U no 25 2 1 1 2 — yes 1 3 2 1 3 3 4 3 5
ALS-07 M possible 45 50 no S 2 L/U yes 35 4 4 4 1 1 — 0 1 4 4 8 4 4 4 5
ALS-08 M possible 52 58 no S 2 L/U no 35 4 4 4 2 2 — 2 2 3 1 4 3 4 4 nd
ALS-09 M definite 40 45 no S 3 L/U no 23 2 2 3 0 0 — 0 0 3 1 4 4 4 4 5
ALS-10 M probable 61 73 nd S 2 L/U no 39 4 4 4 3 3 — 3 3 2 1 3 4 4 4 5
ALS-11 M definite 59 66 no S 4 L/U no 23 3 1 1 0 0 — 0 2 4 4 8 3 2 2 5
ALS-12 F definite 54 55 nd B 3 L/U no 25 2 0 2 2 0 — 1 3 3 1 4 3 4 4 5
K-01 F 76
K-02 M 69
K-03 F 58
K-04 M 72
K-05 F 60
K-06 F 43
K-07 F 70
K-08 M 57
K-09 F 45
K-10 M 46
K-11 M 75
Table 1. Characteristics of patients (ALS) and controls (K). Legend: ALS = patient group, K = control group, 
nd = no data, S = spinal, B = bulbar, L = lower motor neuron, U = upper motor neuron. *Sample ALS-05 was 
excluded from furter analyses due to low RIN.
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such as proteoglycans in cancer and glioma are also among the top hits, this is most probably coincidental due to 
an overabundance of miRNAs studies in cancer and possible muscle atrophy pathway overlap between ALS and 
cancer-associated cachexia.
GO molecular function categories included various parts of RNA metabolism, such as RNA binding, and 
nucleic acid and protein binding transcription factor activity, which are known to be affected in ALS. GO cellular 
compartment categories also included established ALS associated terms, such as protein complex. Interestingly, 
nucleoplasm – the role of which is currently under intense investigation48,49, as well as platelet alpha-granule 
lumen (that contains insulin-like growth factor 1), which has been linked to Alzheimer’s disease50, were also 
among the top GO compartment hits. GO biological processes included over a hundred terms, among them, 
expected apoptotic signaling pathways, but also neurotrophin TRK receptor signaling pathway and muscle cell 
differentiation, supporting previously observed findings that muscle tissue is actively making attempts at regener-
ation during ALS progression51. Additionally, cellular lipid metabolic process, insulin receptor signaling pathway, 
synaptic transmission and axon guidance were also among the biological process GO hits.
Other differentially expressed small RNAs. Our analyses identified over 40 groups of small nucleolar 
RNAs (snoRNAs) to be differentially expressed, of which all but one were upregulated in ALS patients (Table 2). 
All belonged to the C/D box snoRNA family (SNORD) which is associated with methylation of ribosomal RNAs 
Figure 1. (A) Distribution of sequence tag annotations and differentially expressed small RNA species in 
ALS patients. (B) Plots of mean normalized counts against log2 fold change. Dots represent individual tags. 
Significantly differentially expressed tags are shown in red. Significant miRNA (C) and other small RNAs (D) 
identified by both differential analyses and identified in separate patient groups.
Figure 2. PCA plot of all annotated unique sequences, first two components are shown. ALS and control 
samples are clustered together, with the exception of control sample K10 and ALS samples ALS4, ALS7, ALS8, 
and ALS9.
www.nature.com/scientificreports/
5SCIenTIFIC RepoRts |  (2018) 8:5609  | DOI:10.1038/s41598-018-23139-2
and may, therefore, reflect the increased ribosomal turnover as part of the increased protein metabolism during 
compensatory efforts52.
Small RNAs of mitochondrial origin were also significantly differentially expressed, which is in line with aber-
rant mitochondrial function in ALS. Tags mapping to the MT-RNR2 (mitochondrial 16 S RNA) were the only 
ones to be significantly upregulated by both the Baggerly and the DESeq analyses.
Additional differentially expressed ncRNAs include spliced transcripts SNHG1-003//SNHG1-024//SNHG1-
013, involved in neural-stem-cell differentiation53, and GAS5 (growth arrest-specific 5) - small nucleolar RNA 
host gene, that can serve as a decoy for the glucocorticoid and related receptors and promotes apoptosis54.
Discussion
In our analysis of the global differential expression of small RNAs, we identified 758 un-annotated and 134 anno-
tated tags (including miRNAs, snoRNAs, and mtRNAs) to be differentially expressed in the muscle tissue of ALS 
patients. This previously unknown diversity at the level of regulatory RNA molecules may point us toward finding 
novel disease mechanisms as well as the most likely candidates for novel directions in therapy development.
The KEGG and GO analyses of the differentially expressed miRNAs suggest their likely involvement in both 
degenerative/apoptotic processes, as well their involvement in muscle regeneration attempts. Furthermore, sev-
eral of the differentially expressed miRNAs identified in the muscle tissue of ALS patients have previously been 
linked with ALS.
Our results show partial overlap with neuronal studies of associations between miRNAs and ALS. In neu-
ronal models, TDP-43 mutations have been shown to cause differential expression of miR-132, miR-143 and 
miR-558, and TDP-43 deficiency was shown to impair neurite outgrowth in Neuro2a cells, which could then be 
rescued by miR-132 overexpression55. Similarly, FUS has been shown to promote the biogenesis miR-9, miR-132 
and miR-13456, which are miRNAs with a known function in neuronal development and synaptic plasticity57–62. 
Additionally, miR-9 down-regulation was observed in induced pluripotent stem cell derived neurons from an 
ALS patient with a TDP-43 mutation63, whereas miR-155, which is increased in the spinal cord of ALS patients, 
was suggested as a therapeutic target and its inhibition extended surivival in SOD-1-G93A mice36. Recently, miR-
218 has also been suggested to affect motor-neuron loss in a rat hSOD1 WT ALS model rats64.
Of the miRNAs with proposed CNS involvement in ALS, miR-132 and miR-125b, were up-regulated in our 
study. While miR-132 is directly affected by mutations in both TDP-43 and FUS in neuronal models of ALS55,56, 
miR-125b has been connected to neuro-inflammation through NF-kB activation in a SOD-1-G93A microglia 
Figure 3. Clustering of ALS and control samples according to the 50 most highly expressed annotated small 
RNA sequences.
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Small RNA group:miRNAs Expression
All ALS vs. 
controls*
All ALS vs. 
controls**
All ALS vs. 
controls w/o K10**
ALS group 1 vs. 
controls w/o K10**
ALS group 2 vs. 
controls w/o K10**
hsa-miR-100-5p up √ √ √ √
hsa-miR-10a precursor up √ √ √
hsa-miR-125a-5p + precursor up √ √ √
hsa-miR-125b-1/miR-125b-5p + precursor up √
hsa-miR-1260a-5p up √
hsa-miR-126-5p down √
hsa-miR-128-2-3p up √
hsa-miR-1285-1-3p, hsa-miR-1285-1 /miR-1285-2-3p down √
hsa-miR-1291 precursor up √ √ √
hsa-miR-1303-3p down √ √ √ √
hsa-miR-132-5p up √
hsa-miR-133a-1/miR-133a-2-3p + precursor up/down √ √
hsa-miR-150-5p down √ √ √
hsa-miR-151a-5p up √
hsa-miR-191-5p down √
hsa-miR-199a-1//miR-199a-2//miR-199b-3p + precursor up √
hsa-miR-212-5p up √
hsa-miR-214-3p up √
hsa-miR-22 precursor up √
hsa-miR-24-1-5p up √
hsa-miR-26a-1//miR-26a-2-5p down √ √
hsa-miR-26a-1/miR-26a-2-5p + precursor up √
hsa-miR-27a-5p up √
hsa-miR-28-3p down √
hsa-miR-30d precursor down √
hsa-miR-3607-3p up √
hsa-miR-362 up √ √
hsa-miR-378a -3p + miR-378a//miR-378d-2//miR-378c//
miR-378d-1//miR-378e precursor down √
hsa-miR-378c precursor down √
hsa-miR-378d-3p down √
hsa-miR-424-5p up √
hsa-miR-450a-1//miR-450a-2-5p up √
hsa-miR-450b-5p up √
hsa-miR-4662a-5p up √
hsa-miR-486-1//miR-486-2-5p down √ √ √
hsa-miR-494-3p down √
hsa-miR-500a-3p up √ √
hsa-miR-501-3p up √ √
hsa-miR-502-3p up √ √ √
hsa-miR-542-3p up √
hsa-miR-542-5p up √ √
hsa-miR-5699-5p down √
hsa-miR-584-5p down √
hsa-miR-625-3p up √
hsa-miR-660-5p up √
hsa-miR-855-3p down √
hsa-miR-99a-5p + precursor up √ √ √
snoRNAs Expression
All ALS vs. 
controls*
All ALS vs. 
controls**
All ALS vs. 
controls w/o K10**
ALS group 1 vs. 
controls w/o K10**
ALS group 2 vs. 
controls w/o K10**
SNORD100-201 up √
SNORD10-201 up √ √
SNORD102–201 up √
SNORD104–201 up √ √ √
SNORD105B-201 up √
SNORD110–201 up √
Continued
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Small RNA group:miRNAs Expression
All ALS vs. 
controls*
All ALS vs. 
controls**
All ALS vs. 
controls w/o K10**
ALS group 1 vs. 
controls w/o K10**
ALS group 2 vs. 
controls w/o K10**
SNORD115 group up √ √ √ √
SNORD116 group up √ √ √ √ √
SNORD12–201 group (hsa-miR-1259) up √
SNORD12C-201 up √
SNORD13–201 up √
SNORD14C-201 up √
SNORD14D-201 up √
SNORD18A-201 up √
SNORD20-201 up √
SNORD22 group down √
SNORD24 group up √
SNORD26 group up √
SNORD27 group up √
SNORD32A-201 up √
SNORD33–201 up √
SNORD35B-201 up √
SNORD36B group up √
SNORD43 group up √
SNORD45 group up √ √
SNORD46 group up √
SNORD48 group – RNU48 up √ √ √ √
SNORD52 group up √
SNORD5–201 up √
SNORD60–201 up √ √
SNORD61–201 up √
SNORD63–201 up √
SNORD64 group up √
SNORD68–201 up √
SNORD69–201 up √
SNORD8–201 up √
SNORD84 group up √ √ √ √
SNORD93 up √
SNORD95–201 up √ √ √ √
SNORD97–201 up √ √ √ √
SNORD99–201 up √
Mitochondrial origin Expression
All ALS vs. 
controls*
All ALS vs. 
controls**
All ALS vs. 
controls w/o K10**
ALS group 1 vs. 
controls w/o K10**
ALS group 2 vs. 
controls w/o K10**
MT-RNR2–201 up √ √ √ √
MT-TE-201 down √
MT-TF-201 up √ √
MT-TH-201 down √
MT-TL1–201 up √ √ √
MT-TL2-201 up/down √ √
MT-TN down √
MT-TP-201 up √ √
MT-TQ up √
MT-TS2–201 down √
MT-TV-201 up √
MT-TY-201 up/down √ √
MT-TM-201 up √
MT-TC-21 up √
Other ncRNAs Expression
All ALS vs. 
controls*
All ALS vs. 
controls**
All ALS vs. 
controls w/o K10**
ALS group 1 vs. 
controls w/o K10**
ALS group 2 vs. 
controls w/o K10**
AC006041.1–001 lincRNA up √
AC074212.5-002 retained intron down √
AC084082.3-001 lincRNA up √
Continued
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culture model65. Whether miR-125b may act in a similar way in muscle and whether its origin may be the motor 
neurons or neuro-muscular junctions within the muscle tissue, remains to be determined.
A classical myomiR, miR-133a is predicted to target TUBA4A, which was recently shown to be involved in 
ALS66,67, and has also been shown to change during myogenesis68, in response to physical activity69,70, aging71 as 
well as during neuromuscular regeneration and reinnervation in a rat denervation model72, and has recently been 
shown to be increased in early-stage and slow-progressing ALS patients34. Interestingly, our comparison of all 
patients against the controls showed a significant increase, while the comparison of ALS group 1 patients (higher 
disease severity) against controls showed a significant decrease in miR-133a, suggesting it may undergo change 
during disease progression.
Furthermore, miR-133 and miR-30d (that was down-regulated in all patients vs. controls) are repressed by 
insulin in skeletal muscle tissue73 and may be involved in the observed protective role of diabetes against the 
development of ALS74. Of the miRNAs that have already been therapeutically targeted in mice and rats30,36, only 
miR-133a was identified as being differentially expressed in our study and therefore likely represents a good target 
for human therapy development.
In contrast, we did not find changes in the expression of miR-1 or miR-206, despite them being among the 
most highly expressed miRNAs in muscle tissue in general, and despite miR-206 being recently identified as 
a potential biomarker in serum from ALS patients75, as well as increased in muscles of four early-stage ALS 
patients34. This likely reflects the differences in our study populations, i.e., serum of ALS patients with varying 
scores of leg-use in the Waller study, and the muscle tissue of ALS patients with above-average leg-use in our 
study. As miR-206 is highly expressed in human muscle, we postulate that the observed time-dependent differ-
ences in miR-206 observed in the Waller study as well as our observations, indicate that miR-206 may bear direct 
correlation with the deterioration of the muscle tissue, rather than this miRNA being directly involved in ALS 
pathogenesis. The observed difference with the study by Di Pietro et al., is expected, given the different patient 
cohorts, as they have observed a difference in miR-206 expression only in the four patients with early-stage 
Small RNA group:miRNAs Expression
All ALS vs. 
controls*
All ALS vs. 
controls**
All ALS vs. 
controls w/o K10**
ALS group 1 vs. 
controls w/o K10**
ALS group 2 vs. 
controls w/o K10**
AP000233.2-002 lincRNA up √
CTD-2562J15.4 known antisense RNA up √
CTD-2651B20.7-001 CTD-2651B20.6-001 up √ √ √ √
GAS5-006 (growth arrest-specific 5) retained intron up √
GAS5-007 (growth arrest-specific 5) retained intron up √
GAS5-014 (growth arrest-specific 5) lincRNA up √
GAS5-015 (growth arrest-specific 5) lincRNA up √
GAS5-022 (growth arrest-specific 5) retained intron up √
LIMD1-AS1-002 (LIMD1 antisense RNA 1) up √
LINC00293 up √
LINC00324 up √ √ √
LINC01470-006 up √
LINC01783-001 up √
Retired novel miRNA ENST00000616457.1//
ENST00000612700.1// ENST00000611802.1//
ENST00000611393.1//ENST00000612047.1//
ENST00000617883.1
down √
Retired miRNA ENST00000614470.1//ENST00000611934.1//
ENST00000488123.2//ENST00000617236.1 down √
RNA5-8S5 down √ √
RNA5-8SP6-201 (RNA, 58S pseudogene 6) up √
RNVU1-7-201RNA, variant U1 small nuclear 7 up √
RP11-3B12.3-001 up √ √ √
RP11-395B7.2 down √
RP11-473M20.16-001 up √ √ √ √
RP11-1260E13.4 group down √
RP4-561L24.3-001 up √ √ √
RP4-671O14.6-001 known sense overlapping up √
SNHG1-003//SNHG1-024//SNHG1-013 up √ √ √
snoU18.1-201 space novel snoRNA up √
U1 spliceosomal RNA up √
XXbac-BCX254L4.4-001//RP5-1186N24.3-001 down √ √
ZNF436-AS1-201 down √
Table 2. Significantly (FDR corrected p-value ≤0.05, FC ≥2.0) differentially expressed small RNA groups in 
ALS patients vs. controls. ALS group 1 samples include ALS 1, 2, 3, 6, 10, 11, 12, while ALS group 2 samples 
include samples ALS 4, 7, 8, 9. *Baggerly’s test, **DESeq analysis.
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disease (less than 10 months after onset), whereas our study included only two such patients (one year after 
onset), whereas both studies agreed and showed no difference in patients with longer progression.
Similarly, miR-133a and miR-26a were also the only ones, of the differentially expressed miRNAs previously 
observed in muscle tissue of ALS patients using qPCR methods34,51,76, that could be confirmed by our study. 
Indeed, in muscle tissue of ALS patients, miR-29 has been previously observed to increase together with miR-23a, 
miR-29b, miR-206 and miR-45576. Recently, however, the expression of some of these myomiRs (miR-1, miR-23a, 
miR-26a, miR-27b, miR-29b, miR-133a, miR-206, and miR-455) has been re-examined by using qPCR methods 
in muscle samples of ALS patients and controls51, and miR-1, miR-26a, miR-133a, and miR-455 were shown to be 
significantly decreased in patients. The reason for this discordance is likely methodological, as there are no relia-
ble internal control standards for miRNA qPCR yet77–79. Choosing controls for qPCR remains a tremendous chal-
lenge because, during atrophy, skeletal muscle is subject to global morphological changes affecting fiber type and 
overall muscle, vascular and adipose cell content, which in turn affects housekeeping genes51,80–82. Furthermore, 
as will be discussed further, in our study we have detected a significant up-regulation of SNORD48, or RNU48, 
which is a common qPCR control molecule.
Five of our differentially expressed miRNAs have so far also been shown in normal muscle tissue processes. 
MiR-24, miR-26, miR-27, miR-214, and miR-502 were up-regulated, both in cellular models of differentiation 
of satellite cells into myoblasts and myotubules83–89, as well as in our study. This observation strongly suggests 
the myomiRs are actively involved in muscle differentiation and likely play a part in compensatory attempts 
during ALS progression. While miR-125b was found to be down-regulated in the mentioned cellular models of 
muscle differentiation83–89, in our study it was found to be up-regulated, likely reflecting previously discussed 
neuro-inflammatory mechanisms relating to ALS pathogenesis65.
Interestingly, apart from our study, a decrease of miR-468 has so far been observed after acute or chronic exer-
cise90. Although counterintuitive, this may be explained by fasciculations that precede atrophy in ALS. Indeed, 
rather than being inactive and senescent, muscle tissue in ALS is in effect overly active in parallel to atrophy 
development1.
Furthermore, miR-1260a, miR-214, and miR-501 are strongly (miTG score of >0,9) predicted to have bind-
ing sites for controlling TDP-43, a protein central to ALS pathogenesis. Similarly, miR-30d is predicted to target 
Figure 4. Heatmap of KEGG union significance clusters based on miRNA species identified by both Baggerly’s 
test and DESeq.
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C9ORF72, a gene whose intronic expansion mutation is the most common genetic cause of ALS. MiR-30d 
can additionally target CARF, TRPM7, and CHMP3B, all of which were shown to be involved in ALS to var-
ious extents91, and TRPM7 and CARF are also predicted to be targeted by miR-22 and miR-26a, respectively. 
Furthermore, miR-378c may target hnRNPA1, another protein central to ALS pathology9. Finally, miR-1291 is 
predicted to target ATXN2 and DCTN1, while miR-10a is predicted to target ALS2 protein.
Of the differentially expressed snoRNAs, unexpectedly SNORD115, SNORD116, SNORD48, SNORD84, 
SNORD95, and SNORD97 were significantly upregulated in both the Baggerly and DESeq analyses, as well as in 
the ALS group 1 comparisons. Interestingly, SNORD64, SNORD115, and particularly SNORD116 are absent in 
Prader-Willi syndrome92,93, which is characterized by severe hypotonia at birth and later development of obses-
sive eating, morbid obesity and type-2 diabetes94. Additionally, SNORD115 may also target serotonin receptor 
5HT-2C mRNA95. In our study all three were shown to be up-regulated, providing a possible molecular link 
between the observed inverse relationship between ALS, fatty acid metabolism, and diabetes47,74. Unexpectedly, 
SNORD116 was the only small RNA significantly differentially expressed when comparing the ALS group 2 
patients to controls, indicating it may be one of the first observable changes in the muscle tissue of ALS patients 
during disease progression.
SNORD48 also known as RNU48, was shown to be significantly upregulated in ALS patients, adding to 
mounting evidence that this commonly used qPCR internal control should be used with care96,97. While the role 
of SNORD84 and SNORD97 are unknown, SNORD95 is expressed from the intron of the RACK1 (GNB2L1) 
gene, which is involved in translational repression and ribosomal quality control98,99. Moreover, SNORD20 orig-
inates from an intron of the human nucleolin gene, defects in which have been linked with C9ORF72 repeat 
related ALS100.
Of note, MT-RNR2 encodes for humanin peptide, which is associated with apoptosis and insulin sensitivity 
and is thought to be protective in Alzheimer’s and Huntington’s disease101–103. Furthermore, it was found to be 
increased in endurance exercise, again suggesting a link to fasciculations in ALS104.
Caveats
The technical challenges faced in our study include a relatively low number of samples, lack of stable normalizers 
for qPCR validation105–107, and difficulties with functional validation of miRNA targets.
The number of samples in our study was limited by inclusion criteria and ethical considerations. The ability to 
walk was chosen as our main inclusion criteria because the hallmark of ALS is rapidly progressive loss of muscle 
tissue. In immobile patients, the procedure would be unethical, and over three-quarters of the interested patients 
were excluded due to this issue. Despite their low number the collected samples nevertheless represent a valuable 
resource as they were collected from functional muscles of ALS patients, and we were therefore in a unique posi-
tion to identify processes taking place before functional muscle loss.
A traditional approach in expression studies has been to validate global expression results using qPCR. For 
this stable normalizers are needed, but identifying such molecules is often challenging, and needs to be identified 
on a case-by-case basis105–107. Despite attempting to identify appropriate small RNAs for qPCR validation, we 
have not found such molecules, either through the NormFinder108 software nor by in-house methods. The most 
likely explanation is that muscle atrophy, regardless of its cause, is a global process also affecting the expression of 
housekeepers or normalizers. An additional issue is that it is not clear how the numerous identified sub-, super-, 
and precursor variants, would, if at all, be detected by qPCR assays, which specifically target mature miRNAs.
Finally, under ideal conditions, functional validation of miRNA’s target proteins would be performed, as the 
expression on the mRNA level does not directly correlate with miRNA expression. Unfortunately, small muscle 
biopsy size, the large number of changing small RNA molecules and last but not least limited availability of ade-
quate commercial antibodies for target human proteins prevented us from achieving this goal.
Therefore, due to the mentioned caveats and technical limitations, we would like to emphasize that some of 
our conclusions remain speculative, however, they are for the most part consistent with current knowledge and 
we hope our findings will form the basis for further research in this direction.
Conclusions
Our study represents the first, comprehensive differential analysis of small RNA expression in muscle tissue of 
ALS patients. We have identified many differentially expressed miRNAs, some of which have been previously sug-
gested to be associated with known or postulated pathways in ALS, muscle differentiation, and reinnervation, and 
we comment on the similarities and differences with differential expression of miRNAs in ALS in blood, shown 
so far, hopefully highlighting molecules promising as biomarkers or targets in therapy development. We further-
more show that differential expression of small RNAs in ALS includes molecules such as RNU48, considered as 
housekeepers, as well as mtRNAs and snoRNAs involved in other diseases.
Materials and Methods
Ethics statement. Ethical approval of the study (No. 58/11/14) was obtained from the Republic of Slovenia 
National Medical Ethics Committee – NMEC. Written informed consent was obtained from all patients and con-
trols. All methods were performed in accordance with the relevant guidelines and regulations.
Patients and controls. Slovenian patients with amyotrophic lateral sclerosis as well as their spouses or 
other non-blood relatives were invited to participate in the study by either the ALS team coordinator and/or 
treating neurologist at the Ljubljana ALS Centre, Institute of Clinical Neurophysiology, University Medical Centre 
Ljubljana.
The inclusion criteria for all volunteers were the ability to walk/still walk, and having no counter-indications 
for the biopsy procedure, such as receiving anticoagulant therapy. Muscle biopsy samples were collected from 12 
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patients and 11 controls, from February until August 2015. In addition to the muscle biopsies, clinical data were 
also collected at or just prior to the visit. Data collected included the ALS diagnosis according to the revised El 
Escorial score40, staging, age at diagnosis, ALS mutation status, bulbar/spinal onset, upper/lower motor neuron 
deficits, family history of ALS, ALS FRSr and quadriceps strength.
Muscle biopsy procedure. Muscle biopsy procedures were performed on the vastus lateralis muscle using 
a standard procedure by trained physicians who routinely perform the procedure for diagnostic purposes. In 
case of patients, the less affected leg was chosen for the biopsy in order to minimise the possibility of obtaining 
connective tissue and fat rather than muscle.
In short, the site of the biopsy was disinfected and then anesthetized by injecting 2% Xylocaine. After anes-
thetic took hold, a small cut to the skin and fascia was made through which the biopsy sample (10–100 mg) was 
taken using a rongeur instrument. The sample was quickly visually inspected for fat/blood vessels, which were 
removed if present, and then immediately snap frozen in liquid nitrogen and then transferred to −80 °C until 
further analyses. The incision was closed using steri-strips bands and the biopsy site was pressure bandaged for 
a few hours. Instructions were given as to the home care of the biopsy site. One adverse event (hematoma) was 
noted in connection with the biopsy in one of the controls. No adverse events were noticed in any of the patients 
or other controls.
Isolation and sequencing of small RNAs. Extraction of total RNA, library preparation, and 
next-generation small RNA sequencing were performed commercially by IMGM Laboratories GmbH 
(Martinsried, Germany) on Illumina NextSeq 500.
Isolation and quality control. Total RNA was isolated using miRNeasy kit (Qiagen) according to the pro-
tocol of the manufacturer. The final RNA concentration and purity were determined using NanoDrop ND-1000 
spectral photometer (peqlab). In order to determine RNA integrity number (RIN), samples were analyzed on 
the 2100 Bioanalyzer (Agilent Technologies) using the RNA 6000 Nano LabChip Kit (Agilent Technologies). 
Based on the quality of RIN, and RNA concentration and purity, 22 of the 23 samples were selected for small 
RNA library preparation for NextSeq sequencing, while one ALS sample (ALS-5) was excluded from any further 
analyses.
Small RNA library preparation. Illumina® TruSeq® Small RNA Library Prep Kit (Illumina) was used to 
generate small RNA libraries of 22 samples according to manufacturer’s instructions with one human brain total 
RNA sample processed and analyzed in parallel as a positive control. An input of 800–1000 ng of RNA was used 
for library generation.
PCR amplification was performed on the generated single strand cDNA with index primers in order so that 
the samples could be multiplexed for further library analyses. PCR products were purified and size selected using 
gel purification (6% Novex TBE gels) and the purified cDNA constructs were concentrated by ethanol precipita-
tion. Quality control of each library sample was performed using the High Sensitivity DNA LabChip Kit (Agilent 
Technologies) on the 2100 Bioanalyzer (Agilent Technologies) before and after size selection. Library quantifica-
tion prior to normalization was performed using Qubit® dsDNA HS Assay kit (Invitrogen). Post-purification, all 
samples ranged in size between 70 and 155 bp (including adaptor sequences) and were of sufficient concentration 
for RNA sequencing analysis. Libraries were pooled in equimolar ratios for sequencing.
Next generation sequencing. Two single-end 75 base sequencing runs (1x 75 bp SE) were performed with 
the final library on the NextSeq 500 sequencing system (Illumina) under the control of the NextSeq® Control 
Software (NCS) (Illumina), using a PhiX v3 control library spike-in (Illumina). Cluster densities ranged from 
107–119 k/mm2 and two runs per sample were performed in order to obtain a sufficiently high yield per sam-
ple. The two 1 × 75 SE runs had 96.5% and 95.8% >Q30 bases, respectively. Real-Time Analysis 2.4.6 Software 
(RTA) was used to process the primary image on the NextSeq 500 instrument, while primary data analysis was 
performed using the bcl2fastq 2.15.0.4 software package. Sequencing run performance was imaged and evaluated 
using the Illumina Sequence Analysis Viewer (SAV) 1.11.0. QC Results of sequenced samples are summarised in 
Supplementary Table S1.
Bioinformatic analysis
QC, mapping and differential expression analysis. The first part of the bioinformatic data analysis 
was performed commercially by IMGM Laboratories GmbH using CLC Genomics Workbench 8.5.1 (CLC bio). 
Sequencing reads were trimmed, removing the adaptor (RTP 5′ GCCTTGGCACCCGAGAATTCCA), and only 
reads with the length between 15 and 55 bp were selected for further analyses. The number of unique tags (unique 
nucleotide sequence) was counted in each sample (Supplementary Table S1) and the tags were annotated using 
small RNA databases human miRBase 21 and Ensemble Non-coding RNA (GRCh38ncrna), and the ‘Annotate 
and Merge’ tool from CLC Genomics Workbench. Up to two mismatches, no gaps and + /−2 nucleotides were 
allowed to be counted up- and/or downstream from known small RNA sequences in the databases. The mapping 
was performed by allowing no mismatches in the first round of analysis, then allowing one mismatch for the 
unmapped reads in the second round, and finally allowing two mismatches for the remaining unmapped reads 
in the final round of mapping. Each included tag (unique nucleotide sequence) had to be detected at least five 
times, in order to remove possible sequencing artifacts. The analysis resulted in annotated and unannotated set 
of sequences, which were then compared in a pairwise manner between the reference and ALS group (please see 
statistical analyses).
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The second part of the bioinformatic data analysis was performed at the Laboratory of Bioinformatics at the 
University of Ljubljana Faculty of Computer and Information Science.
Additional differential expression analyses including data quality assessment by sample clustering and visuali-
zation were performed with the DESeq software package46 based on the IMGM annotated and unannotated reads 
of ALS patients and controls, as well as on total unique tag counts. For the DESeq analysis based on the IMGM 
annotated and unannotated tags of ALS patients and controls, the reads were filtered prior to the analysis with 
only those tags detected at least five times in at least six samples included in the analysis.
Target, GO and KEGG Pathway analysis. Target analysis was performed on-line using the DIANA tools 
MR-microT software109,110 (Updated to Ensembl v84). The list of identified target proteins was then compared 
against the Ensembl databases and with the help of Ensembl Biomart111,112 to identify proteins known to be 
involved in ALS, other dystrophies, muscle development, and muscle disease.
Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were con-
ducted online using the DIANA-miRPath v3.0. tools113,114 on all 49 differentially expressed miRNAs, including 
their 3′ and 5′ species, identified by both the Baggerly’s test and DESeq in order to identify relevant pathways 
and gene ontologies. All DIANA-miRPath analyses using Tarbase v7.0 were performed with FDR correction and 
conservative statistics options.
Statistical analysis
Patients’ and controls’ characteristics were analyzed by using descriptive methods (average, standard deviation 
(SD)).
Statistical analysis performed commercially by IMGM Laboratories GmbH consisted of a pairwise compari-
son of annotated sequences of ALS patients vs. controls, and unannotated sequences of ALS patients vs. controls, 
using the Baggerley et al.’s test44. Benjamini and Hochberg method was used to calculate the false discovery rate 
(FDR)45. Only tags with at least 5 counts were included in the analysis. In order to achieve significance, both a 
p-value and corrected p-value of ≤0.05 needed to be reached by the changed small RNA. Additionally, a propor-
tion fold change cut-off of 2.0 was implemented, meaning small RNAs were considered induced if the proportions 
fold change (FC) values ≥2.0 and repressed if the value was ≤−2.
In order to validate the results, the count data were further analyzed using the DESeq as an R/Bioconductor 
package, as previously described46.
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